Kornimate/medical-research-clean huggingface dataset:
behavioral economic incentives and cancer health risk assessment

Conditions: Cancer of the Colon

Summary: this is an rct among uphs employees between ages 50-64 comparing no incentive and a loss-framed incentive for completing cancer health risk assessment. those eligible will receive the phone number for direct colonoscopy scheduling, with the incentive arm receiving an additional unconditional incentive. the primary outcome is completion of screening colonoscopy. secondary outcomes include scheduling of colonoscopy and completion of risk assessment.

colorectal cancer (crc) is the second leading cause of cancer death in the united states. despite effective screening and treatment strategies, screening rates remain at 59-65%. uphs employees have similarly limited rates of crc screening despite having awareness, access, and insurance coverage. there is a need to identify those who are not up-to-date on screening and eligible for outreach in this population. financial incentives informed by behavioral economic principles could be used to encourage self-report about screening status and completion of crc screening. this research utilizes a digital health platform, way to health, to evaluate the feasibility of a cancer health risk assessment. this is a single-center rct among uphs employees between ages 50-64 that will randomize eligible participants into one of two study arms: (1) no incentive to complete cancer health risk assessment (no incentive) or (2) loss-framed incentive to complete cancer health risk assessment (incentive). those that are eligible for screening will receive a direct access phone number to schedule colonoscopy, with an additional unconditional incentive for those in incentive arm. the primary outcome is completion of screening colonoscopy, with secondary outcomes of colonoscopy scheduling and completion of risk assessment.

Eligibility criteria:
inclusion criteria: * male and female uphs employees between the ages 50-64 * those who live within 30 miles of the main endoscopy sites exclusion criteria: -minimal exclusion criteria
a study of talquetamab in participants with relapsed or refractory multiple myeloma

Conditions: Hematological Malignancies

Summary: the purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended phase 2 dose(s) (rp2ds) (part 3).


Eligibility criteria:
inclusion criteria: * documented initial diagnosis of multiple myeloma according to international myeloma working group (imwg) diagnostic criteria * part 3: measurable disease cohort a, cohort b, cohort c and cohort d: multiple myeloma must be measurable by central laboratory assessment; cohort e: multiple myeloma must be measurable by local laboratory assessment * eastern cooperative oncology group (ecog) performance status score of 0 to 2 * women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (beta human chorionic gonadotropin \[hcg\]) or urine * willing and able to adhere to the prohibitions and restrictions specified in this protocol exclusion criteria: * part 3 only: cohort a and cohort c only: exposed to a car-t or t cell redirection therapy at any time. cohort b, cohort d and cohort e: t cell redirection therapy within 3 months * toxicities from previous anticancer therapies should have resolved to baseline levels or to grade 1 or less except for alopecia or peripheral neuropathy * received a cumulative dose of corticosteroids equivalent to \>= 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication) * stroke or seizure within 6 months prior to signing the informed consent form (icf)

Keywords: multiple myeloma
evaluation of serum procalcitonin in critically ill patients with suspected sepsis

Conditions: Sepsis

Summary: procalcitonin is a promising marker of sepsis in critically ill patients. procalcitonin have better diagnostic accuracy compared to white blood cell count and c - reactive protein. investigators propose that adding procalcitonin to the list of standard laboratory work up of critically ill patients with suspected sepsis could increase diagnostic accuracy leading to better patient care.

background: sepsis is the leading cause of mortality in critically ill patients. procalcitonin (pct) is a promising marker for identification of bacterial sepsis. the aim of this study was to determine the diagnostic accuracy of serum pct concentration in patients with suspected sepsis admitted to mixed medical-surgical intensive care unit (icu). material and methods: a cross-sectional study conducted at section of chemical pathology, department of pathology and laboratory medicine and icu. patients with suspected sepsis were included, serum pct cut off ≥0.5 ng /ml was taken for diagnosing sepsis. diagnostic accuracy was measured in terms of sensitivity, specificity, positive predictive value (ppv) and negative predictive value (npv) taking blood culture as gold standard. furthermore, different cut offs were compared by using receiver operating characteristic curves (roc). data analysis was done on spss version.

Eligibility criteria:
inclusion criteria: 1. both male and female patients less than 70 and greater than 18 years of age 2. patients full filling the sepsis definition (american college of chest physicians/society of critical care medicine consensus conference) 3. patients were recruited within 24 hour of icu admission exclusion criteria: 1. patients discharged before 24 hours 2. patients who had blood transfusion before icu stay 3. patients with organ failure
evaluating effectiveness of powered drill bone marrow biopsy

Conditions: Plasma Cell Myeloma

Summary: since the introduction of the jamshidi needle in 1971, new advances in bone marrow sampling have not been seen. in 2007, a new battery-powered bone marrow biopsy system was developed. this technology, using a battery-powered drill to operate the needle accessing the posterior iliac bone, was approved by the food and drug administration (fda) and is currently commercially available. few randomized controlled trials (rcts) have compared the use of the battery-powered bone marrow biopsy system to the jamshidi needle (the traditional manual) method of bone marrow sampling. this research study is designed to evaluate the effectiveness of the jamshidi needle compared to the battery-powered bone marrow biopsy system. 100 participants will be enrolled in this study at emory university.

primary objective: i. assessing the quality and quantity of bone marrow core biopsies. secondary objectives: i. assessing the nature of pain by established visual analogue scale (vas) questionnaires. ii. timing of the actual procedure. outline: patients are randomized to 1 of 2 arms. arm i: patients undergo bone marrow biopsy using the power drill. arm ii: patients undergo bone marrow biopsy using the traditional jamshidi needle. all patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7. after completion of study treatment, patients are followed up periodically.

Eligibility criteria:
inclusion criteria: * all patients with existing plasma cell disorders and no history of psychiatric disorders who can receive conscious sedation are eligible to participate in the trial exclusion criteria: * pregnant women are excluded from participating in this study
maps prep van study

Conditions: HIV Infection

Summary: for this study the investigators aim to see if giving participants an oral hiv prevention medication on a medical van, is a good option of care for individuals who inject drugs and/or are sexually active and therefore at a higher risk of contracting hiv.

the purpose of this study is to evaluate a pilot program that provides pre-exposure prophylaxis (prep) for people who use drugs (pwud) and are at risk for contracting hiv. given the ongoing overdose crisis and the risk of hiv among pwud, this study aims to assess weather offering oral prep on a medical mobile unit (mmu) is a viable strategy for preventing hiv transmission in high-risk populations. the other goal of this study is to assess community perceptions of prep and perceived hiv risk among syringe service program (ssp) clients visiting a mmu.

Eligibility criteria:
inclusion criteria: * 18 years or older, active drug injection user and/or sexually active, referred from the syringe service program exclusion criteria: * positive hiv status

Keywords: people who inject drugs mobile medical unit prep syringe service program hiv prevention
effect of palivizumab on later recurrent wheezing in preterm infants

Conditions: Recurrent Wheezing; Wheezing; Asthma

Summary: the hypothesis of the present study is that the prophylaxis with palivizumab to prevent the severe rs virus infection during the infancy among preterm infants may reduce the risk of subsequent recurrent wheezing in childhood. the infants born between july 1st and december 31st in 2007 with the gestational age between 33 and 35 weeks were enrolled into the study at the end of rs virus infection season, april 2008. the infants were unintentionally divided into two groups, either palivizumab treated or untreated group at the enrollment, because the timing for palivizumab prophylaxis were already ended. the study infants will be followed up until the age of 3 with recording the incidence of either parent reported or physician diagnosed recurrent wheezing. the difference of the incidence of the recurrent wheezing between the groups will be analyzed with kaplan-meier method.


Eligibility criteria:
inclusion criteria: * infants born july \~ december 2007 at 33\~35 weeks of gestation exclusion criteria: * intrauterine growth retardation (less than -2.5sd) * infants with chronic lung disease (cld) or other respiratory disease * infants received mechanical ventilation. * infants with chronic heart disease (chd) or congenital anomaly (such as immunodeficiency). * infants received less than 3 doses of palivizumab during the first 6 months of life

Keywords: recurrent wheezing asthma preterm infants palivizumab atopic diseases
can recombinant human intrinsic factor be used for evaluation of the vitamin b12 absorption?

Conditions: Vitamin B12 Deficiency

Summary: vitamin b12 is an essential nutrient for normal dna-synthesis and must be supplied by animal products. vitamin b12 deficiency may cause anemia and irreverible neurological damage. laboratory tests are used for diagnosis of vitamin b12 deficiency, and following the diagnosis, the cause of the vitamin b12 deficiency has to be clarified. for years a test called shilling's test has been used for evaluation of the vitamin b12 absorption. however, the schilling's test is no longer easy accessible because of increasing difficulties to obtain the radioactively labeled vitamin b12 requested, and native human intrinsic factor for schilling's test ii (absorption of vitamin b12 attached to intrinsic factor) is no longer available in most countries. recently, human intrinsic factor unsaturated with vitamin b12 has been expressed in the plant arabidopsis thaliana. the purpose of this study was to examine whether recombinant human intrinsic factor is able to promote the uptake of vitamin b12 in patients with evident vitamin b12 deficiency.

vitamin b12 is an essential nutrient for normal dna-synthesis and must be supplied by animal products. vitamin b12 deficiency may cause anemia and irreverible neurological damage. laboratory tests are used for diagnosis of vitamin b12 deficiency, and following the diagnosis, the cause of the vitamin b12 deficiency has to be clarified. for years a test called shilling's test has been used for evaluation of the vitamin b12 absorption. however, the schilling's test is no longer easy accessible because of increasing difficulties to obtain the radioactively labeled vitamin b12 requested, and native human intrinsic factor for schilling's test ii (absorption of vitamin b12 attached to intrinsic factor) is no longer available in most countries. recently, human intrinsic factor unsaturated with vitamin b12 has been expressed in the plant arabidopsis thaliana. the purpose of this study was to examine whether recombinant human intrinsic factor is able to promote the uptake of vitamin b12 in patients with evident vitamin b12 deficiency.

Eligibility criteria:
inclusion criteria: patients suspected to have vitamin b12 deficiency defined as a plasma vitamin b12 below the reference interval (\<200 pmol/l). exclusion criteria: patients who were pregnant, nursing or not able to give written informed consent were excluded.

Keywords: vitamin b12 deficiency vitamin b12 malabsorption intrinsic factor holotranscobalamin
a polysomnographic study of single-dose gabapentin in transient insomnia

Conditions: Transient Insomnia

Summary: the purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.


Eligibility criteria:
inclusion criteria: * aged \>/= 18 years who reported occasional sleeplessness in the month prior to screening * females of child-bearing potential using medically-acceptable method of birth control \>/= 1 month prior to screening exclusion criteria: * current or recent history (within 2 years) of sleep disorder (excessive snoring, obstructive sleep apnea, chronic painful condition) * currently taking or expected to take any of the following during the trial: amphetamines, benzodiazepines, cocaine, marijuana, methaqualone, methadone, opiates, propoxyphene, barbituates, and phencyclidine
combination chemotherapy of paclitaxel and carboplatin with or without anthracycline as aneo adjuvant treatment in advanced endometrial carcinoma

Conditions: Endometrial Carcinoma

Summary: endometrial cancer, the most common gynecologic cancer worldwide, is steadily increasing in developed countries.the early-stage forms of endometrial cancer are usually highly curable by surgical treatment alone, whereas advanced stages require adjuvant interdictions such as radiotherapy and chemotherapy. platinum and anthracycline drugs have long been used as standard adjuvant chemotherapy drugs for advanced and recurrent endometrial carcinomas. in one study, the standard combination adjuvant treatment with ap was found to be more effective as an adjuvant therapy than whole abdominal irradiation


Eligibility criteria:
inclusion criteria:• age group: histologically diagnosed with primary endometrial carcinoma * more than 20 years old. * any histological type of endometrial carcinoma * stage iii, iv * stage one i or ii with one or more of the following factors: 1. histologic grade 3 endometroid carcinoma with myometrial invasion still within half of the myometrium 2. histological grade 1,2 endometroid carcinomas with invasion of over half of myometrium 3. cervical stromal invasion 4. vascular invasion; or 5. serous carcinoma, clear cell carcinoma, or undifferentiated carcinoma * performance status 0-2 * adequate function of all major organs exclusion criteria: * • pt has received prior radiation or chemotherapy. * pt with sarcomatous component * metastatic endometrial carcinoma * other malignancy * unfit patient for chemotherapy
a study of the safety and efficacy of hylan g-f 20 (synvisc) in patients with symptomatic osteoarthritis of the knee

Conditions: Osteoarthritis, Knee; Musculoskeletal Diseases

Summary: this clinical study is to evaluate the safety and efficacy of hylan g-f 20 (synvisc) in patients with symptomatic knee osteoarthritis (oa). patients will be given 6 ml of hylan g-f 20 (synvisc) (or a phosphate buffered saline control), with a possible repeat treatment with synvisc after the week 26 visit.

the trial included an initial 26 week treatment with 6 ml of hylan g-f 20 (synvisc) (or a phosphate buffered saline control) followed by a 4 week repeat treatment of synvisc.

Eligibility criteria:
inclusion criteria: * patient with documented diagnosis of primary osteoarthritis (oa) of the target knee made at least 3 months prior to screening, * has radiographic evidence of oa in the tibio-femoral compartment of the target, knee with at least 1 definite osteophyte and a measureable joint space, as diagnosed by standard x-rays taken not longer than 3 months prior to screening, and before any baseline assessment, * has continued target knee pain despite conservative treatment (e.g. weight reduction, physical therapy, analgesics), * has pain in the target knee as demonstrated by a score of 2 or 3 on the western ontario and mcmaster universities osteoarthritis index likert scale version 3.1 (womac lk 3.1) a1 (walking pain) subscale , * has a mean score of 1.5 to 3.5 on the western ontario and mcmaster universities osteoarthritis index likert scale version 3.1 (womac lk 3.1) a (pain) subscale. * inclusion criteria for repeat phase: must have no major safety concerns during the first course of treatment as assessed by the investigator; must have a womac lk 3.1 a score of at least 1. exclusion criteria: * has modified kellgren-lawrence numerical grading system of grade iv in the patello-femoral compartment of the target knee confirmed by standard x-rays taken not longer than 3 months prior to screening, and before any baseline assessment, * has clinically apparent tense effusion of the target knee, * has had viscosupplementation in any joint including the target knee within 9 months prior to screening, * has concomitant inflammatory disease or other condition that affects the joints (e.g. rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active infection, etc.,) * symptomatic oa of the contralateral knee or of either hip that is not responsive to paracetamol and requires other therapy, * has related hypersensitivities to avian proteins and/or any components of hyaluronan-based injection devices,

Keywords: osteoarthritis of the knee musculoskeletal
diagnostic analysis of oral glucose tolerance test in early pregnancy for gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus in Pregnancy

Summary: the aim of this study is to explore the diagnostic efficacy of oral glucose tolerance test in early pregnancy and establish the prediction model for gestational diabetes mellitus, so as to provide the optimal screening of gestational diabetes mellitus in the first trimester. the treatment started when the pregnancy was confirmed by transvaginal ultrasound (around 6 weeks of gestation) and continued until 42 days postpartum. the study is a single center, prospective cohort study. a total of 781 participants within 14 weeks of gestation were recruited.


Eligibility criteria:
inclusion criteria: * 1. intrauterine pregnancy within 7-14 weeks of gestation * 2. 20-45 years of age * 3. singleton pregnancy * 4. giving informed consent and willing to participate in this study * 5. planning to give birth in women's hospital school of medicine zhejiang university exclusion criteria: * 1. pre-existing diabetes * 2. taking medications that may affect blood glucose levels within one month * 3. participating in other intervention studies * 4. recurrent abortion, threatened abortion, cervical incompetence or fetal malformation

Keywords: gestational diabetes mellitus first trimester prediction model
the effect of pure prone positioning therapy for the patients with mild to moderate obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: efficacy of pure prone positioning (ppp) treatment in improving apnea-hypopnea index (ahi) and nocturnal oxygen saturation was investigated in mild to moderate obstructive sleep apnea.

sleeping in prone position could be effective in the management of obstructive sleep apnea (osa) by reducing the gravity effect on the upper airway and hence collapsibility. pure prone positioning (ppp) consisted of a pillow mounted on a table designed to keep the subjects sleeping prone with the head extended in line with the body.

Eligibility criteria:
inclusion criteria: * patients were enrolled to the study among one hundred and eighty-four consecutive patients who were admitted to our sleep center with 6 beds in a tertiary care hospital, during 3 months period. of these, 36 patients with mild to moderate osa (ahi=5-30 events/h) were invited to participate in the study based on the selection criteria, and 29 patients with mild to moderate osa on their baseline psg, (17 males, 12 females) gave informed consent and participated in the study. exclusion criteria: * patients having bmi\>35 and/or abdominal and/or trunkal obesity that may hinder prone sleeping , upper airway pathology (nasal polyp, nasal turbinate hypertrophy, chronic sinusitis, nasal septum deviation, upper airway infection, mallampati score and tonsil size grade of iv), any other concomitant sleep disorder (narcolepsy, periodic leg movement syndrome, insomnia, sleep related hypoventilation-hypoxemia and central sleep apnea syndrome), psychiatric disorder such as panic disorder, heart failure and coronary artery disease were not included in the study.

Keywords: obstructive sleep apnea prone positioning positional treatment hypoxemia
oil-based vs. water-based contrast medium in hysterosalpingography for infertile women in improving fertility outcome

Conditions: Infertility

Summary: the goal of this clinical trial is to compare the effects of oil-based contrast medium (obcm) and water-based contrast medium (wbcm) during hysterosalpingography（hsg）on pregnancy outcomes in infertile women. the main question it aims to answer is whether an oil-based contrast medium improves fertility outcomes in infertile women. participants were divided into those who received an oil-based contrast medium (ethiodized poppyseed oil) and a water-based contrast medium (ioversol) based on a shared medical decision-making process between patients and healthcare providers. the two contrast agents used in this study are routinely employed in clinical practice and will not affect the participants\&#39; health. participants are required to complete some clinical questionnaires before and after the hsg procedure to provide clinical information. other than that, there will be no additional costs for participants.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. infertility for at least one year without the use of contraceptives. exclusion criteria: 1. endocrine disorders, including cushing's syndrome, hypothalamic amenorrhea, adrenal hyperplasia, diabetes, or thyroid dysfunction (except for well-controlled hypothyroidism with a tsh level between 0.3 and 4.0 miu/l) 2. known allergy to contrast agents, specifically iodine 3. male partner infertility, defined as post-wash sperm motility \&lt;3 million/ml or \&lt;1 million/ml without sperm washing 4. contraindications for undergoing hsg 5. refusal to provide informed consent.

Keywords: infertility hysterosalpingography fertility outcome oil-based contrast medium water-based contrast medium
ultra low dose ct for cacs and ac of spect

Conditions: Coronary Artery Disease

Summary: the aim of the study is to compare the cacs obtained from standard dose ct to the cacs obtained from ultra-low-dose scans. additionally, the usefulness of ultra-low-dose ct for ac of myocardial perfusion spect will be assessed.


Eligibility criteria:
inclusion criteria: * patients referred for myocardial perfusion spect * male and female subjects ≥18 years of age, * written informed consent exclusion criteria: * pregnancy or breast-feeding * cacs of 0 after inclusion of 10 patients with cacs 0 * stents or implanted cardiac devices (valves, pace makers, icd) * coronary artery bypass grafts